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Abstract
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and highly aggressive
hematological malignancy with a poorly understood pathobiology and no effective
therapeutic options. Despite a few recurrent genetic defects (eg, single nucleotide
changes, indels, large chromosomal aberrations) have been identified in BPDCN, none
are disease-specific, and more importantly, none explain its genesis or clinical behavior.
In this study, we performed the first high resolution whole-genome analysis of BPDCN
with a special focus on structural genomic alterations by using whole-genome
sequencing and RNA sequencing. Our study, the first to characterize the landscape of
genomic rearrangements and copy number alterations of BPDCN at nucleotide-level
resolution, revealed that IKZF1, a gene encoding a transcription factor required for the
differentiation of plasmacytoid dendritic cell precursors, is focally inactivated through
recurrent structural alterations in this neoplasm. In concordance with the genomic data,
transcriptome analysis revealed that conserved IKZF1 target genes display a loss-of-
IKZF1 expression pattern. Furthermore, up-regulation of cellular processes responsible
for cell-cell and cell-ECM interactions, which is a hallmark of IKZF1 deficiency, was
prominent in BPDCN. Our findings suggest that IKZF1 inactivation plays a central role
in the pathobiology of the disease, and consequently, therapeutic approaches directed
at reestablishing the function of this gene might be beneficial for patients.
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1 | INTRODUCTION
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and
highly aggressive hematological malignancy derived from neoplastic
plasmacytoid dendritic cell (pDC) precursors. Patients with BPDCN
have infiltration of malignant cells characterized by the expression of
CD4, CD56, CD123, and CD303 in the skin, bone marrow, lymph
nodes, and peripheral blood. The median overall survival of patients
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with BPDCN ranges from 12 to 14 months as the disease typically
relapses after initial response to chemotherapy.1,2
The pathogenetic basis of BPDCN has been investigated using
DNA and RNA array-based methods, and more recently, next gen-
eration sequencing (NGS) approaches limited to the exome (whole-
exome sequencing) or a panel of genes (targeted sequencing).
Recurrent copy number alterations (CNAs) in BPDCN include
broad deletions within chromosomes 7, 9, 12, 13, and 15, particu-
larly the regions containing tumor suppressors CDKN2A/B,
CDKN1B, and RB1.3-6 Overexpressed genes with pathogenic rele-
vance include BCL2 and CCND1.7 Single nucleotide variants (SNVs)
and indels presumed as pathogenic have been observed predomi-
nantly in genes involved in cell cycle control (eg, ATM, TP53), chro-
matin regulation (eg, ASXL1, IDH2, NPM1, TET2), signal
transduction (eg, KRAS, NRAS), splicing (eg, ZRSR2) and transcrip-
tional regulation (eg, IKZF1/2/3, ZEB2).8-11 Additionally, cytoge-
netic studies, most of them performed in the context of case
reports, have revealed chromosomal rearrangements involving
ALK, ETV6, EWSR1, KMT2A (MLL), MYB, MYC, and SUPT3H in a
handful of cases.12-18
Even though these studies have uncovered a variety of genetic
abnormalities in BPDCN, none of the reported alterations has pro-
vided a clear biological rationale behind neither the genesis of the dis-
ease nor its clinical behavior. Furthermore, as yet no study has
characterized the landscape of genomic rearrangements and CNAs of
BPDCN using high resolution NGS.
Here, we present the first whole-genome analysis of BPDCN with
a special emphasis on structural anomalies by using whole-genome
sequencing (WGS) and RNA sequencing (RNA-seq). We report recur-
rent IKZF1 inactivation by focal structural alterations, a loss-of-IKZF1
expression pattern and overexpression of adhesion signatures in
BPDCN. Our findings on genome and transcriptome level not only
support IKZF1 inactivation as a putative driver event in the develop-
ment of BPDCN, but also provide a conceptual basis for the pathobi-
ology of the disease.
2 | MATERIALS AND METHODS
2.1 | Patient material
Frozen tumor biopsies from 10 patients with BPDCN (Table S1) were
subjected to WGS. Four samples of this cohort (ie, BDN1, BDN4,
BDN5, and BDN6) were additionally subjected to RNA-seq. Diagnosis
was performed by an expert panel of dermatologist and pathologists
according to the criteria of the WHO-EORTC classification for pri-
mary cutaneous lymphomas.2,19,20 Frozen tumor biopsies from
15 additional patients were used for validation purposes (extension
cohort) (Table S1). Patient material was approved by the institutional
review boards of Fondazione IRCCS Ca' Granda Ospedale Maggiore
Policlinico, Leiden University Medical Center and University of Pavia.
Informed consent was obtained from patients in accordance with the
declaration of Helsinki.
2.2 | Nucleic acid isolation
Genomic DNA was isolated using Genomic-tip 20/G kit (Qiagen).
DNA purity was evaluated with a Nanodrop One system (Nanodrop
Technologies, Wilmington, California) and DNA integrity was verified
by gel electrophoresis (0.7% agarose, ethidium bromide). Total RNA
was isolated using RNeasy mini kit (Qiagen). RNA integrity was veri-
fied with an Agilent 2100 Bioanalyzer.
2.3 | Sequencing and data processing
Sequencing was performed by the Beijing Genomics Institute (BGI)
and data was processed at Leiden University Medical Center (LUMC).
DNA libraries were subjected to paired-end sequencing (2 × 150 bp)
on the Illumina HiSeq X-Ten platform while RNA libraries derived
from rRNA-depleted total RNA were subjected to paired-end
sequencing (2 × 100 bp) on the Illumina HiSeq 4000 platform. Raw
reads (WGS, RNA-seq) were processed using in-house pipelines and
clean reads were aligned to human reference genome Hg38
(Table S2). WGS and RNA-seq data have been deposited in the
European Genome-Phenome Archive (EGA) under study number
EGAS00001003660.
2.4 | Detection of genomic rearrangements and
fusion transcripts
Detection of structural genomic variants (SV) was performed using an
in-house pipeline that included three structural variant callers
(Breakdancer-max v1.4.4, CleverSV v2.0rc3 and Delly v0.6.7)
(Table S3). SV calls were manually verified and curated using the
Integrative Genomic Viewer (IGV, v2.3.78). The expression of fusion
transcripts was investigated in four BPDCN samples with available
RNA-seq data using an in-house pipeline that included two fusion
transcript callers (FusionCatcher v0.99.6a and Star Fusion v0.8.0)
(Table S4). Fusion transcript calls were contrasted with genomic SV
data and visually verified on DNA level using IGV. Rearranged genes
implicated in cancer were identified using the Network of Cancer
Genes 6.0 (NCG 6.0)21 and literature search.
2.5 | Detection of CNAs
Control-FREEC was used to identify CNAs using a 50 Kb window.
The output was subjected to a Wilcoxon rank test and a Kolmogorov-
Smirnov test to generate a list of genomic regions with statistically
supported CNAs, and the latter were intersected to define recurrent
events. As a complement, GISTIC2.0 analysis was performed with seg-
ment files derived from Control-FREEC (Figure S1, Table S5). Recur-
rent CNAs derived from both analyses were visually verified and
curated using IGV (Table S6). Only CNAs confirmed after inspection
are reported.
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2.6 | Detection of SNVs and indels
SNVs and indels were detected using GATK (v3.5). Variants filtered
out of the output included SNVs present in dbSNP, SNVs with >5%
minor allele frequency in the Exome aggregation consortium (ExAC)
database, and SNVs present in an in-house cohort formed by
11 healthy volunteers. We searched for deleterious SNVs in 1271
genes taking part in signal transduction pathways, the cell cycle,
hematopoietic cell differentiation, and cellular processes previously
identified as mutated in BPDCN.8-10 Gene lists were retrieved from
the PathCards database (http://pathcards.genecards.org/). Only SNVs
predicted to produce highly deleterious amino acid substitutions by
both SIFT and PolyPhen-2 were further investigated on ClinVar, COS-
MIC, Varsome, and literature.
2.7 | Differential expression analysis
TMM normalization was applied to raw count data using EdgeR and
differential expression analysis was performed using Limma-Voom.
BPDCN samples were compared to a control group formed by resting
pDCs. RNA-seq data of pDC controls were generated by Alculumbre
et al and downloaded from GEO (https://www.ncbi.nlm.nih.gov/geo/;
GSE84204).22 Genes with a FDR < 0.01 were considered differentially
expressed (DE).
2.8 | Gene ontology annotation and transcriptome
analysis
Gene ontology annotation of rearranged genes and pathway analysis
with DE genes were performed using DAVID (v6.8) using default set-
tings.23 Gene set enrichment analysis (GSEA, v2.2.4) was run as a pre-
ranked analysis with 1000 permutations using gene set KEEG from
the Molecular Signatures Database (MSigDB).24 Normalized enrich-
ment scores (NES) were calculated to determine expression signa-
tures. FDR q values were obtained. Additional functional
characterization of the transcriptome (ie, ENCODE and CORUM data-
bases) was performed using Enrichr.25
2.9 | Validation of structural genomic alterations
and small-scale mutations
Select genomic rearrangements, interstitial deletions, indels, and SNVs
were validated by Sanger sequencing. Briefly, target sequences were
amplified by PCR, run on a 1% agarose gel, column-purified and
sequenced on the Applied Biosystems ABI3730xl platform. Validation
of select CNAs was performed using Bio-Rad QX200 droplet digital
PCR (ddPCR) system. ddPCR experiments were carried out following
the manufacturer's guidelines. Briefly, 20 to 40 ng of genomic DNA
was mixed with a frequent-cutting restriction enzyme, ddPCR super-
mix, probes against the gene of interest (FAM-labeled) and probes
against the reference gene (HEX-labeled). The reaction mix was then
partitioned into 20.000 nanodroplets, and subsequently, subjected to
the following cycling program: 95C for 10 minutes, 39 cycles of 94C
for 30 seconds, and 60C for 1 minute, and 98C for 10 minutes.
Copy number values were determined using Bio-Rad Quantasoft soft-
ware v1.7.4. Copy number reported for IKZF1 (at exons 1, 5, and 8) in
samples from the validation cohort are the average of 3 independent
measurements using different reference genes.
3 | RESULTS
3.1 | Landscape of genomic rearrangements
BPDCN displayed a heterogenous landscape of rearrangements. We
detected a total of 86 rearrangements in 10 BPDCN genomes
(Figure 1). The number of events per patient ranged from 1 to
18 (mean/patient ± SD, 9 ± 5) (Figures 2A and S2). Intrachromosomal
events constituted 66% of all rearrangements (range/patient, 0%-
100%) (Figure 2B). We observed events joining either two annotated
genes (32% of events), a gene with a nongenic region (36%), two
nongenic regions (27%), or rearranging sequences within a single gene
(5%) (Figure 2C).
Genomic rearrangements disrupted a total of 54 genes across
10 patients (Table S7). Out of 54 rearranged genes, 13 are implicated
in cancer at present (Figure 1, Table S8). The latter group included
genes implicated in hematological malignancies (ie, AHI1, CD36,
IKZF1, MLLT4, MYB, TFG) and other neoplasms (ie, FAT1, IQGAP2,
NRG1, PIK3C2G, PMS1, PPFIBP1, PTPRD). Gene ontology analysis
showed that rearranged genes primarily encode proteins that partici-
pate in cellular component organization (esp. cytoskeleton-related
processes), cell adhesion and transcriptional regulation (Figure 2D,
Table S9).
We observed two recurrently rearranged genes, MYB and TMTC1,
both of them in 2 of 10 patients. The type of MYB rearrangements
found in our patients (BDN3 and BDN10) have been previously
described in BPDCN and result in a gain-of-function effect due to the
loss of the 30-end of the gene which contains conserved target sites
for inhibitory microRNAs (miRNAs).16 In contrast, the observed
TMTC1 rearrangements do not seem to have analogous functional
consequences (ie, dissimilar breakpoint positions, loss vs gain of DNA,
genic vs nongenic partner sequences). We detected additional
rearrangements reported in cancer before. An oncogenic
rearrangement involving SUPT3H, found in patient BDN1, has been
previously described in BPDCN.18 Also, fusion gene NAV2-TCF7L1,
found in patient BDN7, is recurrent in colorectal cancer.26
Notably, we identified rearrangements leading to IKZF1 inactiva-
tion. Fusion gene TMTC1-IKZF1, found in patient BDN6, had a trun-
cated coding sequence (CDS) encoding a peptide constituted only by
the first 77-AA of TMTC1 due to the formation of a premature stop
codon; thus, preventing the synthesis of a functional IKZF1 protein
(Figures 2E and 5C). Another patient, BDN2, underwent a
chromothripsis-like event in chromosome 7 that resulted in the
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deletion of several focal areas within 7p and 7q, including a narrow
region (450 Kb) containing IKZF1 (Figure 2F).
3.2 | Landscape of CNAs
BPDCN exhibited a predominance of large-scale chromosomal imbal-
ances. Broad numerical aberrations (>3 Mb) included monosomy
9 (four patients), as well as deletions within 3p (two patients), 6q (five
patients), 7p (three patients), 9p (two patients), 9q (three patients),
12p (three patients), 13q (six patients), 15q (two patients), and Y (two
patients). Also, broad gains within 1q (three patients), 7q (two
patients) and 12q (two patients) (Figures 3 and 4).
We detected seven focal (≤3 Mb) minimal common regions
(MCRs) between CNAs affecting our sequenced patients (Table S6).
Out of seven focal MCRs, six contained either bona fide or candidate
cancer genes. These focal MCRs were deletions at 9q21.32, 7p12.2,
13q14.2, 6q25.1, 12p13.1, and 7p14.1-p14.2 observed in eight,
seven, six, five, four, and three out of 10 sequenced patients, respec-
tively (Figure 4). Cancer genes residing within these regions are mainly
involved in hematopoiesis and cell cycle regulation.
The most common focal MCRs were deletions at 9q21.32 and
7p12.2 which contained, respectively, tumor suppressors HNRNPK
and IKZF1. HNRNPK encodes a nuclear ribonucleoprotein that
influences multiple cellular functions (eg, cell cycle, chromatin remo-
deling, RNA synthesis, and processing) in hematopoietic cells.27 IKZF1,
on the other hand, encodes a transcription factor with critical roles in
the development of various hematopoietic lineages, including
pDCs.28-31 Remarkably, deletions at 7p12.2 were considerably narrow
(<500 Kb) in four of seven affected patients, ranging from loss of
IKZF1 and a few neighboring genes, to loss of the IKZF1 locus exclu-
sively, to loss of IKZF1's exon 8 only (Figure 5A,B). Patients where
deletions did not involve the whole locus, but part of it, enclosed
exons encoding IKZF1's functional domains (Figure 5B). For instance,
the loss of exon 8 in patient BDN1 generated a CDS encoding an
IKZF1 protein that lacked its C-terminal dimerization domain, which is
essential for its functionality (Figure 5D).
Deletions at 13q14.2 and 6q25.1 encompassed, respectively, RB1
and SYNE1. RB1 encodes an established negative regulator of the cell
cycle whereas candidate tumor suppressor SYNE1, which is often
silenced by hypermethylation in lung cancer,32 encodes a
cytoskeleton-associated protein that helps maintain subcellular spatial
organization.
Deletion at 12p13.1 included tumor suppressors CDKN1B,
DUSP16, and ETV6 which play roles in the cell cycle, signal transduc-
tion and hematopoiesis, respectively. Finally, deletion at 7p14.1-p14.2
enclosed tumor suppressor SFRP4, a negative regulator of WNT
signaling.
F IGURE 1 Landscape of genomic
rearrangements in BPDCN. Circos plot
showing 86 genomic rearrangements
detected in 10 BPDCN genomes by
WGS. The outer ring is formed by
human chromosome ideograms
arranged circularly end to end. The
area at the center of the plot contains
arcs representing interchromosomal
(blue) and intrachromosomal (red)
events. The ring between the
chromosome ideograms and the arcs
contains rearranged genes with
established roles in cancer. BPDCN,
blastic plasmacytoid dendritic cell
neoplasm; WGS, whole-genome
sequencing [Color figure can be
viewed at wileyonlinelibrary.com]
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3.3 | Small-scale mutations
We looked for small-scale mutations (ie, indels, SNVs) with potential
pathogenic relevance in exonic sequences of genes involved in the cell
cycle, hematopoietic cell differentiation, signal transduction (ie, JAK-
STAT, MAPK, NF-κB, and PI-3-K/Akt signaling pathways) and genes
that have been previously found to be mutated in BPDCN (Table S10).
Two gain-of-function SNVs, BRAF (p.G464V33) and NRAS (p.
E63K34), were observed in patient BDN5. NRAS (p.G12A35), a SNV
associated with melanoma and lung cancer, was found in patient
BDN2. Truncating frameshift mutations in ASXL1 (p.E635Rfs*15, p.
V624Gfs*8) were observed in BDN4/9 and BDN7, respectively. Also,
seven patients carried indels and SNVs leading either to premature
stop codons or amino acid substitutions predicted as deleterious in
F IGURE 2 Distribution of genomic rearrangements and gene ontology annotation of rearranged genes in BPDCN. A, Number of genomic
rearrangements per patient. The distribution of inter- and intrachromosomal rearrangements per patient is shown too; B, Distribution of inter-
and intrachromosomal rearrangements (cohort); C, Distribution of genomic rearrangements based on the type of DNA sequences (genic,
nongenic) involved in the event (cohort); D, Distribution of rearranged genes according to the biological process their encoded protein
participates in; E, Circos plot showing interchromosomal rearrangement t(7;12)(p12;p11) in patient BDN6 which fuses TMTC1 with IKZF1, causing
the inactivation of the latter. F, Circos plot displaying a chromothripsis-like event in patient BDN2 which mediated the loss of several focal
regions in chromosome 7, including a narrow area (450 Kb) containing IKZF1. BPDCN, blastic plasmacytoid dendritic cell neoplasm [Color figure
can be viewed at wileyonlinelibrary.com]
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TET2. (Figures 4, S3, and S4). Of note, we found mutations in IKZF1
(ie, BDN9: p.H421Afs*68, BDN4: p.H480Y) that impacted the dimer-
ization domain of this gene. The former mutation generates an IKZF1
protein with a truncated dimerization domain while the latter leads to
an amino acid substitution predicted as deleterious (Figures S3
and S4).
Finally, we found 24 additional patient-specific SNVs of unknown
significance in cancer-associated genes, including genes previously
implicated in BPDCN (ie, ARID1A, ASH1L, ASXL3, ATR, CBLC, CHD8,
EP400, ETV6, PHC2, RAD52, SMARCD1, SRSF2, and ZRSR2) (Table S11).
3.4 | DE genes
Prior research using array-based gene expression profiling showed
that BPDCN cells appear to originate from pDC precursors that are
phenotypically close to resting pDCs.7 Therefore, to determine DE
genes in the disease, we compared gene expression in BPDCN with
gene expression in resting pDCs. The analysis uncovered 1827 DE
genes (1191 up-regulated, 636 down-regulated, FDR < 0.01)
(Figure 6A, Table S12), 272 of which are currently associated with
cancer (213 up-regulated, 64 down-regulated) (Table S13). Up-
regulated genes included (proto-) oncogenes with roles in apoptosis
(ie, BCL2, TERT), cell cycle regulation (ie, FOXM1), hematopoietic cell
development (ie, AFF3, MYB), and signal transduction (ie, BCL9,
FGFR1,MET, PDGFRA, PDGFRB, PLCG1, RRAS2) (Figure 6B). Prominent
down-regulated genes included cell cycle inhibitors (ie, BTG2, IFIT3,
TSPYL2, TXNIP) and tumor suppressors implicated in hematological
malignancies (ie, PTPRO, SAMD9L) (Figure 6B).
F IGURE 3 Landscape of CNAs in BPDCN. Human chromosome ideograms displaying regions of gain and loss detected through WGS in
10 BPDCN genomes. Blue bars to the right of the chromosomes depict regions of loss whereas red bars to the left of the chromosomes depict
regions of gain. BPDCN, blastic plasmacytoid dendritic cell neoplasm; CNAs, copy number alterations; WGS, whole-genome sequencing [Color
figure can be viewed at wileyonlinelibrary.com]
F IGURE 4 Distribution of recurrent CNAs and deleterious indels/
SNVs in BPDCN. Upper panel: large CNAs (>3 Mb). Middle panel:
focal MCRs (≤3 Mb) between CNAs; reputable tumor suppressors
enclosed within focal MCRs are specified. Bottom panel: Indels and
SNVs either leading to protein truncations, reported as pathogenic in
literature or predicted as deleterious (SIFT and PolyPhen-2) are
shown. Only genes mutated in more than one patient are indicated.
BPDCN, blastic plasmacytoid dendritic cell neoplasm; CNAs, copy
number alterations; MCRs, minimal common regions; SNVs, single
nucleotide variants [Color figure can be viewed at
wileyonlinelibrary.com]
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Transcriptome analysis with Enrichr using ChIP-seq data from
ENCODE revealed that genes regulated by EZH2, TCF12, and
FOXM1 are greatly overrepresented in the group of up-regulated
genes (Figure 6C, Table S14). EZH2 is part of polycomb repressive
complex 2 (PRC2), a gene silencing protein complex that influences
various cellular processes, including hematopoietic cell differentia-
tion.36 Transcription factor TCF12, on the other hand, participates in
T-cell differentiation and is typically lowly expressed in mature
pDCs.37 Finally, transcription factor FOXM1, which is overexpressed
in numerous cancers, takes part in multiple biological processes (eg,
apoptosis, cell cycle, DNA damage response).38
Since IKZF1 deletion was the most focal recurrent CNA in our
sequenced cohort, we next looked at the expression of a group of evo-
lutionarily conserved IKZF1 target genes that are associated with the
development of BCR-ABL1+ pre-B acute lymphoblastic leukemia (pre-B
ALL)39,40 (Table S15), an aggressive hematological cancer characterized
by IKZF1 inactivation. We detected 29 DE cancer-associated IKZF1 tar-
get genes (25 up-regulated, 4 down-regulated) in BPDCN (Figure 6D).
The expression of all IKZF1 target genes matched perfectly the
expected consequence of IKZF1 deficiency; that is, genes repressed by
IKZF1 were up-regulated while genes activated by IKZF1 were down-
regulated. Genes of interest in the group of up-regulated IKZF1 targets
included among others, CCND1, CDC42BPB, and IFITM3. Cyclin D1
(encoded by CCND1) promotes G1/S transition in the cell cycle and has
been previously found to be overexpressed in BPDCN.7 CDC42BPB
encodes a serine/threonine kinase with roles in cytoskeletal reorganiza-
tion and cell migration.41 Interestingly, overexpression of this kinase
has been shown to facilitate cancer cell invasion.42 Finally, IFITM3
encodes an antiviral membrane protein that has been shown to trigger
CD19-mediated PI-3-K/Akt signaling in pre-B ALL.43
3.5 | Deregulated processes/pathways
We performed pathway analysis with DAVID to identify deregulated
cellular processes/pathways in BPDCN. The analysis uncovered up-
regulation of several adhesion profiles: ECM-receptor interaction
(P = 2.51 × 10−15), focal adhesion (P = 5.61 × 10−14), adherens junction
(P = 2.64 × 10−5), and Rap1 signaling (P = 4.58 × 10−5). BPDCN also
displayed up-regulation of PI-3-K/Akt signaling (P = 6.46 × 10−11) and
the cell cycle (P = 8.22 × 10−5) (Figure 6E, Table S16). Down-regulated
cellular processes included ribosome synthesis (P = 3.34 × 10−17), oxi-
dative phosphorylation (P = 4.11 × 10−12) and protein processing in the
endoplasmic reticulum (ER) (P = 6.98 × 10−6) (Figure 6F, Table S16). To
complement DAVID analysis, we performed GSEA using gene set KEEG
from MSigDB. GSEA confirmed that BPDCN is characterized by the
up-regulation of adhesion signatures (Figure 6G, Table S17). Impor-
tantly, these deregulated profiles support an IKZF1-deficient pheno-
type of BPDCN cells, as previous studies performed by others have
established that a hallmark of IKZF1 deficiency in immune cells (ie,
pDCs, pre-B cells) is the overexpression of proteins responsible for cell-
cell and cell-ECM interactions.29,44
Additionally, we identified a group of up-regulated genes
encoding components of the integrin-cytoskeleton network that have
been proven to undergo up-regulation as a result of IKZF1 deficiency
in murine models of pre-B ALL (Figure 6H).44 One of these genes,
THY1 (CD90), encodes a membrane glycoprotein involved in integrin
signaling and adhesion. Notably, THY1 is one of the key surface mole-
cules underlying the highly adhesive phenotype of IKZF1-deficient
malignant cells in BCR-ABL1+ pre-B ALL.45,46 Another gene, CTTN,
encodes cortactin, a cytoplasmic protein that participates in the for-
mation of podosomes in motile cells. Cortactin overexpression occurs
in a number of aggressive cancers and promotes the formation of
invadopodia (hyperactive podosomes) which make malignant cells
highly invasive and migratory.47 Interestingly, transcriptome analysis
with Enrichr using CORUM database predicted the existence of pro-
tein complex DDEF1-CTTN-PXN in BPDCN cells (Figure 6I,
Table S18). This cytoskeleton-associated protein complex has been
found exclusively in malignant cells with highly invasive behavior
(breast cancer), and not in their noninvasive or normal counterparts.48
3.6 | Structural alterations involving IKZF1 are
recurrent in BPDCN
Since the findings derived from our genome and transcriptome ana-
lyses strongly pointed at IKZF1 as a central player in the pathogenesis
of BPDCN, we next used ddPCR to assess the copy number of IKZF1
F IGURE 5 Interstitial deletions and rearrangements inactivate IKZF1 in BPDCN. A, Diagram representing the hemizygous loss of IKZF1
(217 Kb-3.8 Mb) in BPDCN tumors. Blue bars depict deleted areas at 7p12.2 in tumors from three patients with BPDCN. Monoallelic IKZF1
deletion occurred through narrow interstitial deletions in patients BDN3 and BDN10, and through a complex intrachromosomal rearrangement in
patient BDN2 (see also Figure 2F); B, Diagram showing inactivating structural changes at the IKZF1 locus in BPDCN tumors. These events
included narrow interstitial deletions (BDN1/9) and an unbalanced interchromosomal rearrangement (BDN6). The breakpoints of all IKZF1-
inactivating structural alterations were validated by Sanger sequencing. Genomic coordinates of breakpoints according to reference genome
Hg38. Arrows indicate the direction toward which genomic coordinate numbers increase. Plus (+) and minus (−) signs specify strand polarity; C,
The fusion between TMTC1 and IKZF1 in patient BDN6 generated a truncated coding sequence (77-AA) due to the formation of a premature stop
codon (shown in RNA-seq reads), rendering IKZF1 inactive on protein level. D, Sashimi plots showing RNA expression at IKZF1 in patient BDN1
(purple) and control sample pDC3 (green). Due to a focal interstitial deletion (blue bar), the transcript of IKZF1 in patient BDN1 lacks exon 8, and
instead includes a readthrough sequence starting from exon 7 toward the remaining part of the 30-UTR and beyond. The resulting transcript
encodes a functionally defective IKZF1 protein that lacks its dimerization domain. BPDCN, blastic plasmacytoid dendritic cell neoplasm; CTX,
interchromosomal rearrangement; iDel, interstitial deletion; ITX, intrachromosomal rearrangement [Color figure can be viewed at
wileyonlinelibrary.com]
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in tumors from 15 additional patients. Because our genomic data
showed that IKZF1-disrupting unbalanced rearrangements and dele-
tions did not affect the entire locus in all patients, but deleted only
the 50-end or the 30-end of IKZF1 in some of them (Figures 5B and
7A), we evaluated copy number at three different exons (ie, 1, 5, and
8). Exons 1, 5, and 8 encode, respectively, the leader sequence (50-
UTR), two of the four Zn fingers forming the DNA-binding domain,
and the dimerization domain of IKZF1.
CNAs involving IKZF1 were detected in 6 of 15 (40%) patients
from the extension cohort, 5 of which had deletions (Figure 7B). Inter-
estingly, one patient (BDN15) displayed normal copy number at exon
1 and 8, but a gain at exon 5, suggesting a focal duplication of one or
more exons within the IKZF1 locus (Figure 7B). Of note, focal exon
duplications in tumor suppressors can generate inactivating frame-
shifts, as documented in BRCA1.49 Overall, combining the sequenced
and extension cohorts, 13 of 25 patients (52%) had structural alter-
ations involving IKZF1.
4 | DISCUSSION
In this study we describe the first high resolution whole-genome anal-
ysis of BPDCN using WGS. Our analysis, which focused on structural
genomic alterations, identified 54 genes disrupted by rearrangements
which are predominantly involved in cytoskeleton-associated pro-
cesses, adhesion and transcriptional regulation. Out of 54 rearranged
genes, 13 are involved in malignancies at present, being IKZF1 and
MYB the only cancer genes recurrently impacted by rearrangements
in our sequenced cohort. We identified 6 recurrently deleted genomic
regions enclosing recognized tumor suppressors (ie, CDKN1B, ETV6,
HNRNPK, IKZF1, RB1, and SFRP4) with important roles in hematopoie-
sis and cell cycle regulation. In addition, deleterious indels and SNVs
in ASXL1, IKZF1, NRAS, and TET2 were recurrent in our patients.
IKZF1 inactivation, which mainly occurred through narrow inter-
stitial deletions (9.5 Kb-3.8 Mb) and unbalanced rearrangements, was
the most prominent alteration in BPDCN due to its focality, recur-
rence, and likely adverse effects during early development of pDCs.
The latter is supported by the fact that IKZF1 deficiency keeps pDC
precursors stuck at an early differentiation stage whereas function-
impairing changes in both IKZF1 alleles lead to absence of pDCs in
murine models.29,31 Using an independent cohort, we confirmed by
ddPCR that structural alterations at the IKZF1 locus are recurrent in
BPDCN. Although the incidence of CNAs involving IKZF1 was lower
in the extension cohort compared to the sequenced cohort (difference
not statistically significant, P > .05, Fisher's exact test), patients with
normal IKZF1 copy number might still carry inactivating balanced
rearrangements, indels or SNVs which do not entail numerical
changes. In agreement with the recurrent IKZF1 inactivation observed
in BPDCN, transcriptome analysis revealed that conserved IKZF1 tar-
get genes show a clear loss-of-IKZF1 expression pattern.
Even though the roles of IKZF1 in hematopoiesis and leukemogen-
esis are only starting to be understood, it is currently well-established
that insufficiency of functional IKZF1 proteins leads to overexpression
of adhesion molecules, surface receptors and ECM proteins in immune
cells, as demonstrated in murine pDC precursors carrying hypomorphic
Ikzf1 alleles (eg, Igll1, Mmp14, Ncam1 [Cd56], Thy1, etc.),29 murine B cell
precursors engineered to produce Ikzf1 proteins lacking DNA-binding
ability (eg, Itga9, Itgb3, Lamb1, Mmp14, etc.)44 and malignant cells
derived from murine models of BCR-ABL1+ pre-B ALL carrying loss-of-
function mutations in Ikzf1 (eg, Cd28, Itga5, Thy1, etc.).45,46 Our data, in
full concordance with this evidence, suggest that IKZF1 inactivation lies
behind the up-regulation of adhesion profiles in BPDCN.
BPDCN displayed up-regulation of the PI-3-K/Akt pathway and the
Rap1 pathway. The PI-3-K/Akt pathway, often overactivated in human
cancers, promotes cancer cell proliferation. Notably, IKZF1 has been
shown to transcriptionally repress components of the PI-3-K/Akt path-
way (eg, PIK3CD, PIK3C2B, PIP4K2B, etc.),50 and concordantly,
IKZF1-deficient malignant cells from murine models of pre-B ALL show
overactivation of PI-3-K/Akt signaling.44 Hence, IKZF1 deficiency in
BPDCN might underlie or contribute to the observed overactivation of
the PI-3-K/Akt pathway. In contrast, the Rap1 pathway regulates cell
motility and integrin-mediated adhesion in leukocytes, lymphocytes and
dendritic cells, both of which are processes hijacked by neoplastic cells
to disseminate to other body sites.51 In fact, activation of Rap1 signaling
has been shown to trigger migration of T-acute lymphoblastic leukemia
and B-cell lymphoma cells, in vitro and in vivo, respectively.52,53
We found that genes silenced by PRC2 (EZH2) were the most over-
represented in the group of up-regulated genes in BPDCN. This agrees
F IGURE 6 RNA-seq supports a loss-of-IKZF1 phenotype in BPDCN and uncovers aberrant cell adhesion in the disease. A, Heat map showing
1827 differentially expressed genes (1191 up-regulated, 636 down-regulated, FDR < 0.01) in BPDCN when compared to resting pDCs. B, (Proto)-
oncogenes and tumor suppressors involved in cell cycle regulation, hematopoietic cell differentiation and signal transduction are differentially
expressed in BPDCN. C, Genes regulated by EZH2, TCF12, and FOXM1 are the most overrepresented in the group of up-regulated genes. D,
Conserved IKZF1 target genes follow a loss-of-IKZF1 expression pattern in BPDCN; that is, genes repressed by IKZF1 are up-regulated while
genes activated by IKZF1 are down-regulated. E, F, Pathway analysis using DAVID uncovered up-regulation of cellular processes responsible for
cell-cell and cell-ECM interactions, the PI-3-K/Akt pathway, the Rap1 pathway and the cell cycle. Down-regulated profiles included ribosome,
oxidative phosphorylation and protein processing in the endoplasmic reticulum (ER) (See Table S16 for a complete list of enriched terms/
processes). G, Gene set enrichment analysis (GSEA) confirmed that BPDCN is characterized by the up-regulation of adhesion signatures. NES,
normalized enrichment score; FDR q-value, false discovery rate q-value. (See Table S17 for a complete list of GSEA signatures). H, Genes
encoding components of the integrin-cytoskeleton network, which have been shown to undergo up-regulation due to IKZF1 deficiency in BCR-
ABL1+ pre-B ALL, are up-regulated in BPDCN as well. I, Protein complex DDEF1-CTTN-PXN is predicted to exist in BPDCN cells based on
transcriptome data. This complex has only been found in neoplastic cells with an invasive phenotype. BPDCN, blastic plasmacytoid dendritic cell
neoplasm; CPC, chromosomal passenger complex; NDC80, NDC80 kinetochore complex [Color figure can be viewed at wileyonlinelibrary.com]
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with a previous report of a loss-of-EZH2 expression signature in tumor
cells from patients with highly aggressive BPDCN.54 Remarkably, it has
been established that IKZF1, which predominantly acts as a transcrip-
tional repressor, silences genes in erythroid and T-cell precursors by rec-
ruiting PRC2 to target sites.55,56 Thus, up-regulation of genes silenced by
PRC2 in BPDCN might result from shortage of functional IKZF1 mole-
cules, which in turn, would hinder PRC2 recruitment to target sites.
Interestingly, analysis of DE genes in BPDCN not only confirmed
up-regulation of BCL2 and MYB as described in previous studies,7,16
but also uncovered additional up-regulated (proto-) oncogenes of
interest. AFF3, for instance, encodes a transcriptional activator
expressed in early lymphoid development which appears to be
leukemogenic in patients with pre-B ALL carryingMLL-AFF3 fusions.57
FOXM1, on the other hand, promotes cell proliferation and dissemina-
tion in a plethora of neoplasms by inducing cell cycle progression (esp.
at G2/M) and the acquisition of an invasive phenotype.38 RRAS2,
which encodes a small GTPase involved in PI-3-K/Akt signaling, has
been found to be overexpressed in a number of lymphoid malignan-
cies, including cutaneous T cell lymphoma (CTCL).58 Other prominent
up-regulated oncogenes encode receptors (ie, FGFR1, MET, and
PDGFRA/B) that signal through the PI-3-K/Akt pathway.
In addition, we identified in BPDCN a group of down-regulated
genes encoding cell proliferation inhibitors. BTG2, a member of the
BTG/Tob family, stops the cell cycle at G1/S by down-regulating
F IGURE 7 Evaluation of an extension cohort confirms recurrent structural alterations at IKZF1 in BPDCN. A, IKZF1-deleting events detected
by WGS in BPDCN tumors were validated using ddPCR. Copy number was evaluated at exon 1, 5, or 8 according to the region of IKZF1 found to
be deleted by WGS in each affected patient (ie, exon 1:50-end; exon 5: whole locus; exon 8:30-end). B, The existence of recurrent structural
alterations at IKZF1 was confirmed in an extension cohort by ddPCR. Copy number was evaluated at three different exons in all samples to
account for CNAs affecting only the 50-end (exon 1), the middle section (exon 5) or the 30-end (exon 8) of IKZF1. Exons 5 and 8 encode two of the
four Zn fingers forming the DNA-binding domain and the dimerization domain of IKZF1, respectively, being both critical for its functionality. Ctrl,
normal T cells. BPDCN, blastic plasmacytoid dendritic cell neoplasm; CNAs, copy number alterations; WGS, whole-genome sequencing
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cyclin D1, or at G2/M by preventing binding between cyclin B1 and
CDK1.59 IFIT3 and TXNIP, which increase expression of p21/p27 and
p27, respectively, promote cell cycle arrest at G0/G1.60,61 TSPYL2
triggers the inhibition of several cell cycle kinases (ie, CDK1, 2, 4, 6),
halting the cell cycle at multiple phases (G1 to M).62
It has not escaped our notice the apparent parallelism between
BPDCN and BCR-ABL1+ pre-B ALL in terms of deregulated genes
and cellular processes. We hypothesize that these similarities are
rooted in the recurrent inactivation of IKZF1 occurring in both neo-
plasms. This may also explain the positive effects of ALL-like therapy
for the treatment of patients with BPDCN.
In summary, our data strongly supports IKZF1 inactivation as a key
event in the development of BPDCN. First, IKZF1 was found to be
inactivated by structural alterations in 7 of 10 patients from our
sequenced cohort, and recurrent IKZF1 inactivation was confirmed in an
extension cohort. Secondly, expression of conserved IKZF1 target genes
in BPDCN was fully consistent with a loss-of-IKZF1 phenotype. Thirdly,
expression signatures in BPDCN matched known physiological conse-
quences of IKZF1 deficiency (ie, aberrant adhesion, activation of the
PI-3-K/Akt pathway) in immune cells. Finally, since IKZF1 is critical for
pDC differentiation, its abrogation can be expected to derail normal
development of pDC precursors, conceivably leading to their
malignization.
Based on our findings, we suggest that counteracting the patho-
genic loss-of-IKZF1 phenotype of malignant cells in BPDCN through
pharmacological induction of the wild-type IKZF1 allele (eg, by using
retinoids)45 might have beneficial therapeutic effects on patients with
BPDCN.
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